Amgen (AMGN) Comments Following Repatha Patent Win
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) today announced that a Delaware jury delivered a verdict in Amgen's favor in a trial on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE